A Customer-centric, Innovative
and Reliable CDMO with Global Solutions
About Porton
Porton Pharma Solutions, a global company with R&D, and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercial.
5
Regulated Markets
Approval
4200+
Global
Employees
1200+
R&D
Scientists
~2200
Total
Capacity (m³)
1200+
Global
Customers
4000+
Milestone
Projects
Corporate Culture
Mission & Vision
Enabling the public's early access to good medicines.
Values
・Customers First
・Teamwork
・Efficient Execution
・Embrace Changes
・Pursuit of Excellence
・Teamwork
・Efficient Execution
・Embrace Changes
・Pursuit of Excellence
Our Journey To Excellence
Started CMO2005-2008
Became a Public Company2009-2016
Transformed to a Global Leading CDMO2017 to date
Started CMO2005-2008
2005s
2005
Porton Founded
2006
Started CMO (Changshou) With R&D (Chongqing & Chengdu)
2008
Established Porton USA & Europe(Sales), Shanghai (R&D)
Became a Public Company2009-2016
2009s
2013
1st USFDA Inspection With Zero 483
2014
Listed On Shenzhen StockExchange
Transformed to a Global Leading CDMO2017 to date
2017s
2017
Acquired J-Star Research Inc. (USA)
2020
Passed EMA Inspection, Started DP CDMO Services
2021
Acquired Hubei Plant (China)
2022
Started DP Commercial Plant Operation; Acquired Fengxian (Shanghai) GMP Plant
2023
Started Shanghai Headquarters, DP Facility in USA, DS Facility in EU (Slovenia), Tides and Conjugates Facility in Shanghai
2024
Slovenia Site R&D Facility Operation; Changshou Site Passed USFDA Inspection with Zero 483
